PURPOSE: Insomnia is increasingly recognized as a major symptom outcome in breast cancer; however, little is known about its prevalence and risk factors among women receiving aromatase inhibitors (AIs), a standard treatment to increase disease-free survival among breast cancer patients. METHODS: A cross-sectional survey study was conducted among postmenopausal women with stage 0-III breast cancer receiving adjuvant AI therapy at an outpatient breast oncology clinic of a large university hospital. The insomnia severity index (ISI) was used as the primary outcome. Multivariate logistic regression analyses were performed to evaluate risk factors. RESULTS: Among 413 participants, 130 (31.5 %) had subthreshold insomnia on the ISI, and 77 (18.64 %) exceeded the threshold for clinically significant insomnia. In a multivariate logistic regression model, clinically significant insomnia was independently associated with severe joint pain (adjusted odds ratio (AOR) 4.84, 95 % confidence interval (CI) 1.71-13.69, P = 0.003), mild/moderate hot flashes (AOR 2.28, 95 % CI 1.13-4.60, P = 0.02), severe hot flashes (AOR 2.29, 95 % CI 1.23-6.81, P = 0.015), anxiety (AOR 1.99, 95 % CI 1.08-3.65, P = 0.027), and depression (AOR 3.57, 95 % CI 1.48-8.52, P = 0.004). Age (>65 vs. <55 years; AOR 2.31; 95 % CI 1.11-4.81; P = 0.026) and time since breast cancer diagnosis (<2 vs. 2-5 years; AOR 1.94; 95 % CI 1.02-3.69; P = 0.045) were also found to be significant risk factors. Clinical insomnia was more common among those who used medication for treating insomnia and pain. CONCLUSIONS: Insomnia complaints exceed 50 % among AI users. Clinically significant insomnia is highly associated with joint pain, hot flashes, anxiety and depression, age, and time since diagnosis.
PURPOSE:Insomnia is increasingly recognized as a major symptom outcome in breast cancer; however, little is known about its prevalence and risk factors among women receiving aromatase inhibitors (AIs), a standard treatment to increase disease-free survival among breast cancerpatients. METHODS: A cross-sectional survey study was conducted among postmenopausal women with stage 0-III breast cancer receiving adjuvant AI therapy at an outpatient breast oncology clinic of a large university hospital. The insomnia severity index (ISI) was used as the primary outcome. Multivariate logistic regression analyses were performed to evaluate risk factors. RESULTS: Among 413 participants, 130 (31.5 %) had subthreshold insomnia on the ISI, and 77 (18.64 %) exceeded the threshold for clinically significant insomnia. In a multivariate logistic regression model, clinically significant insomnia was independently associated with severe joint pain (adjusted odds ratio (AOR) 4.84, 95 % confidence interval (CI) 1.71-13.69, P = 0.003), mild/moderate hot flashes (AOR 2.28, 95 % CI 1.13-4.60, P = 0.02), severe hot flashes (AOR 2.29, 95 % CI 1.23-6.81, P = 0.015), anxiety (AOR 1.99, 95 % CI 1.08-3.65, P = 0.027), and depression (AOR 3.57, 95 % CI 1.48-8.52, P = 0.004). Age (>65 vs. <55 years; AOR 2.31; 95 % CI 1.11-4.81; P = 0.026) and time since breast cancer diagnosis (<2 vs. 2-5 years; AOR 1.94; 95 % CI 1.02-3.69; P = 0.045) were also found to be significant risk factors. Clinical insomnia was more common among those who used medication for treating insomnia and pain. CONCLUSIONS:Insomnia complaints exceed 50 % among AI users. Clinically significant insomnia is highly associated with joint pain, hot flashes, anxiety and depression, age, and time since diagnosis.
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Janet S Carpenter; Julie L Elam; Sheila H Ridner; Pam H Carney; Gloria J Cherry; Heather L Cucullu Journal: Oncol Nurs Forum Date: 2004-05 Impact factor: 2.172
Authors: Barry V Fortner; Edward J Stepanski; Stephanie C Wang; Sarah Kasprowicz; H Heith Durrence Journal: J Pain Symptom Manage Date: 2002-11 Impact factor: 3.612
Authors: Jun J Mao; H Irene Su; Rui Feng; Michelle L Donelson; Richard Aplenc; Timothy R Rebbeck; Frank Stanczyk; Angela DeMichele Journal: Breast Cancer Res Date: 2011-01-20 Impact factor: 6.466
Authors: Manali A Bhave; Kelly A Speth; Kelley M Kidwell; Angela Lyden; Cindy Alsamarraie; Susan L Murphy; N Lynn Henry Journal: Clin Breast Cancer Date: 2017-12-27 Impact factor: 3.225
Authors: Nicole J Gervais; Luke Remage-Healey; Joseph R Starrett; Daniel J Pollak; Jessica A Mong; Agnès Lacreuse Journal: J Neurosci Date: 2018-12-26 Impact factor: 6.167
Authors: Laurence Leysen; Astrid Lahousse; Jo Nijs; Nele Adriaenssens; Olivier Mairesse; Sergei Ivakhnov; Thomas Bilterys; Eveline Van Looveren; Roselien Pas; David Beckwée Journal: Support Care Cancer Date: 2019-07-25 Impact factor: 3.603
Authors: Sara Vargas; Michael H Antoni; Charles S Carver; Suzanne C Lechner; William Wohlgemuth; Maria Llabre; Bonnie B Blomberg; Stefan Glück; Robert P DerHagopian Journal: Int J Behav Med Date: 2014-12
Authors: Alice C Shapiro; Susan A Adlis; Kim Robien; Mark N Kirstein; Shuang Liang; Sara A Richter; Rachel E Lerner Journal: Breast Cancer Res Treat Date: 2016-02-11 Impact factor: 4.872
Authors: Cathleen Y Xing; Michelle Doose; Bo Qin; Yong Lin; Tiffany L Carson; Jesse J Plascak; Kitaw Demissie; Chi-Chen Hong; Elisa V Bandera; Adana A M Llanos Journal: Breast Cancer Res Treat Date: 2020-09-10 Impact factor: 4.872